7,511.79

+134.93

+1.83%

52,057.08

+771.35

+1.50%

25,145.05

+565.62

+2.30%

2,807.82

+53.71

+1.95%

4.8550

-0.0040

-0.08%

21.53

-4.11

-16.05%

4,126.10

+51.20

+1.26%

74,875.52

-1,091.02

-1.44%

Crude Oil Dec 26

87.51

-3.32

-3.66%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

Curanex Pharmaceuticals Inc (CURX)

6.21 0.00 (0.00%)

As of November 6 at 4:00:00 PM EST. Market Open.

Loading Chart for CURX

Chart Range Bar

Interval:

In partnership with ChartIQ

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

Curanex Forms World Class Scientific Advisory Board

Curanex Forms World Class Scientific Advisory Board

Curanex Provides Operational Update on Key Regulatory Milestones

Curanex Provides Operational Update on Key Regulatory Milestones

Mobilize your Website

View Site in Mobile | Classic

Share by: